Navigation Links
Volcano Reports 22 Percent Increase in Second Quarter Medical Segment Revenues and Earnings per share of $0.09
Date:8/1/2011

SAN DIEGO, Aug. 1, 2011 /PRNewswire/ -- Volcano Corporation (NASDAQ: VOLC), a leading developer and manufacturer of precision intravascular diagnosis and therapy guidance tools designed to enhance the treatment of coronary and peripheral artery disease, said today that revenues for the second quarter of 2011 increased 14 percent versus the second quarter a year ago in total, including a 22 percent increase in medical segment revenues versus the second quarter a year ago.

For the quarter ended June 30, 2011, Volcano reported revenues of $84.0 million versus revenues of $73.5 million in the second quarter a year ago. The company reported net income on a GAAP basis of $4.9 million, or $0.09 per diluted share, in the second quarter of 2011, versus net income on a GAAP basis of $5.4 million, or $0.10 per diluted share, in the second quarter of 2010.

Year-over-year the company's medical segment revenues increased 22 percent for the first quarter of 2011 and 24 percent for the first half of 2011. Industrial segment revenues in the second quarter declined 59 percent year-over-year and 44 percent in the first half of 2011 versus the first half of 2010 - due to the downturn in the telecom industry.

For the first six months of 2011, Volcano reported revenues of $165.0 million, an 18 percent increase over revenues of $140.0 million in the same period a year ago. The company reported GAAP net income of $6.0 million, or $0.11 per diluted share, in the first six months of 2011. This compares with GAAP net income of $1.4 million, or $0.03 per diluted share, in the same period in 2010.

"During the quarter, we continued to successfully drive our initiatives to achieve market share gains and increase utilization for our core FM (Functional Management) and IVUS (Intravascular Ultrasound) offerings. Year-over-year revenues from the sale of IVUS and FM disposables increased 22 percent and 54 percent, respectively," said Scott Huennekens, president and chief executive officer of Volcano.

"We experienced a solid quarter in Japan as activity in the country is beginning to return to normal levels following the tragic earthquake and tsunami in March. Our IVUS disposable revenues there increased 31 percent year-over-year and we have recently launched enhanced versions of our IVUS and FM disposables, as well as the VIBE® RX Vascular Imaging Balloon Catheter that provides precise, targeted balloon dilation using our intravascular imaging technology," Huennekens added.

"Our continued investments in product development and clinical programs are advancing our long-term growth strategy and fulfilling our goal of being the leading therapy guidance company. We are successfully expanding beyond a diagnosis-only company to becoming a platform company delivering precision guided therapy  of minimally invasive diagnosis and therapy utilizing visualization, physiology and other technologies that could double our potential addressable markets to more than $3.0 billion over the next several years," he continued.

Guidance for 2011

The company said it continues to expect that revenues for fiscal 2011 will be in the range of $342-$347 million. It expects that gross margin for the year will be 65-66 percent. This compares to prior guidance for gross margin of 64-65 percent. It now expects operating expenses to be 58-60 percent of revenues for the year. This compares to prior guidance for operating expenses of 57-59 percent of revenues. The company maintained its guidance for earnings per diluted share of $0.19-$0.21 for 2011.

Conference Call Information

The company will hold a conference call at 2 p.m., Pacific Daylight Time (5 p.m., Eastern Daylight Time), today. The teleconference can be accessed by calling (631) 291-4555, passcode 81779990, or via the company's website at http://www.volcanocorp.com. Please dial in or access the webcast 10-15 minutes prior to the beginning of the call. A replay of the conference call will be available through August 8, at (404) 537-3406, passcode 81779990, and via the company's website at http://www.volcanocorp.com.

About Volcano

Volcano Corporation is revolutionizing the medical device industry with a broad suite of technologies that make imaging and therapy simpler, more informative and less invasive. Our products empower physicians around the world with a new generation of analytical tools that deliver more meaningful information - using sound and light as the guiding elements. Founded in cardiovascular care and expanding into other specialties, Volcano is changing the assumption about what is possible in improving patient outcomes by combining imaging and therapy together. For more information, visit the company's website at www.volcanocorp.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release regarding Volcano's business that are not historical facts may be considered "forward-looking statements." Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that may cause Volcano's actual results to differ materially and adversely from statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ include the pace and extent of market adoption of the company's products and technologies, growth strategies, the impact of events in Japan, timing and achievement of product development milestones, outcome of ongoing litigation, the impact and benefits of market development, dependence upon third parties, product introductions, unexpected new data, safety and technical issues, market conditions and other risks inherent to medical and/or telecom device development and commercialization. These and additional risks and uncertainties are more fully described in Volcano's filings made with the Securities and Exchange Commission, including our recent annual report on Form 10-K for the year ended December 31, 2010, and other filings made with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Volcano disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.VOLCANO CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands) (Unaudited) June 30, December 31,20112010 Assets Current assets: Cash and cash equivalents

$
35,433$
43,429 Short-term available-for-sale investments  

170,222175,283 Accounts receivable, net

61,50859,133 Inventories

47,45640,499 Prepaid expenses and other current assets

7,5126,643 Total current assets

322,131324,987 Long-term available-for-sale investments

45,07326,804 Property and equipment, net

62,90556,503 Intangible assets, net

15,99017,103 Goodwill

2,4872,487 Other non-current assets

3,9143,682$
452,500$
431,566 Liabilities and Stockholders' Equity Current liabilities: Accounts payable

$
3,511$
3,895 Accrued compensation

16,59718,241 Accrued expenses and other current liabilities

19,99821,960 Deferred revenues

5,7495,898 Current maturities of long-term debt

7256 Total current liabilities

55,92760,050 Long-term debt

93,43091,236 Deferred revenues

2,6882,466 Other

3,2783,478 Total liabilities

155,323157,230 Stockholders' equity

297,177274,336$
452,500$
431,566VOLCANO CORPORATIONCONSOLIDATED STATEMENTS OF OPERATIONS(in thousands, except per share data)(Unaudited)Three Months Ended
June 30,Six Months Ended
June 30,2011201020112010Revenues

$

84,036

$

73,452

$

165,031

$

140,024Cost of revenues26,76327,09354,63753,731Gross profit57,27346,359110,39486,293Operating expenses:Selling, general and administrative35,48830,08270,94863,161Research and development13,3219,59426,40919,452Amortization of intangibles8586211,7121,194In-process research and development-33-65Total operating expenses49,66740,33099,06983,872Operating income7,6066,02911,3252,421Interest income23283475168Interest expense(2,056)(11)(4,061)(18)Exchange rate (loss) (291)(423)(679)(544)Other-(9)(1)(19)Income before provision for income taxes5,4915,6697,0592,008Provision for income taxes6032531,015628Net income

$

4,888

$

5,416

$

6,044

$

1,380Net income per share:Basic

$

0.09

$

0.11

$

0.12

$

0.03Diluted

$

0.09

$

0.10

$

0.11

$

0.03Shares used in calculating net income per share:Basic52,27250,45252,02050,099Diluted54,53653,07154,43052,876VOLCANO CORPORATIONREVENUE SUMMARY(in millions)(unaudited)Three Months Ended
June 30,Percentage Change Six Months Ended
June 30,Percentage Change 201120102010 to 2011201120102010 to 2011Medical segment:Consoles:United States

$  5.7

$  7.3

(23)

%

$  11.6

$  11.5

%Japan

0.5

0.1

5961.2

1.3

(11)Europe

2.5

2.0

234.8

3.9

24Rest of world

1.1

1.4

(19)2.1

2.7

(21)Total Consoles

$  9.8

$10.8

(9)$  19.7

$  19.4

1IVUS single-procedure disposables:United States

$19.7

$17.1

15 

%

$  37.9

$  33.4

14 

%Japan

22.7

17.3

3144.9

33.2

35Europe

6.2

5.2

2011.7

10.5

11Rest of world

1.4

1.3

113.1

2.4

30Total IVUS single-procedure disposables

$50.0

$40.9

22$  97.6

$  79.5

23FM single-procedure disposables:United States

$  8.7

$  6.0

46 

%

$  16.8

$  11.3

49 

%Japan

1.0

0.7

502.0

1.5

29Europe

6.3

3.7

7011.3

7.7

48Rest of world

0.6

0.4

431.2

0.8

42Total FM single-procedure disposables

$16.6

$10.8

54$  31.3

$  21.3

47Other

$  4.9

4.3

14 

%

$
9.8

8.0

22 

%Sub-total medical segment

$81.3

$66.8

22$158.4

$128.2

24Industrial segment

$  2.7

6.7

(59)$
.6

11.8

(44)Total

$84.0

$73.5

14$165.0

$140.0

18
'/>"/>

SOURCE Volcano Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Volcano Corporation Presentation at Wells Fargo Conference to be Webcast
2. Volcano Corporation Presentation at William Blair Conference to be Webcast
3. Volcano Corporation Presentation at Goldman Sachs Conference to be Webcast
4. Statement From Volcano Corporation on Latest St. Jude Lawsuit
5. Volcano to Highlight its Precision Guided Therapy Technologies at EuroPCR
6. Volcano Achieves 22 Percent Increase in First Quarter Revenues; Sales Growth, Margin Expansion Drive Profitability
7. Volcano Corporation to Supply Intravascular Ultrasound Technology to Covidien for Integration with Plaque Excision Systems
8. Volcano Corporation Presentation at Bank of America Merrill Lynch Conference to be Webcast
9. Volcano Corporation Presentation at JMP Securities Conference to be Webcast
10. Volcano Corporation Schedules First Quarter Conference Call, Webcast
11. Volcano Announces the Introduction of the PrimeWire PRESTIGE® Pressure Guide Wire in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... , First quarter 2016 adjusted diluted earnings per share ... , First quarter reported diluted (GAAP) loss per share ... revises 2016 financial guidance; now expects 2016 revenues to range ... non-GAAP earnings per share to range from $4.50 to $4.80 ... and manufacturing facility restructuring , Company expands ...
(Date:5/5/2016)... Calif. , May 5, 2016  Diagnostic ... a decade due to concerns that these tests ... the approach to imaging, as well as the ... new era of medical peripherals that help health care providers ...   Ampronix  advanced medical imaging is a renowned authorized ...
(Date:5/5/2016)... DUBLIN , May 5, 2016 ... for PET Imaging in Top 5 EU Markets"  report to ... This report provides information on the current Positron Emission ... Five European Markets (T5 EU), which includes France ... , Spain and the ...
Breaking Medicine Technology:
(Date:5/6/2016)... ... May 06, 2016 , ... The National Association of Chain ... in Puerto Rico. Radio messages set to debut on Monday, May 9, and ... about ways to protect themselves and their unborn children from the effects of ...
(Date:5/6/2016)... ... May 06, 2016 , ... DrugDev President ... the way the pharmaceutical industry conducts clinical trials. This month Ibs was named No. ... in pharma, and he was honored as a Tech Disruptor by the Philadelphia Business ...
(Date:5/6/2016)... , ... May 06, 2016 , ... ... Integration Service, their latest implementation service offering for global clients of Coupa ( ... ). , Bluvault’s Integration Service is a key component in the suite ...
(Date:5/6/2016)... ... May 06, 2016 , ... From May 4 to 6, EarQ ... the unique opportunity to learn more about Signia’s technology and the successful business and ... is our priority to see practices succeed in this highly competitive industry,” said Ed ...
(Date:5/6/2016)... ... May 06, 2016 , ... Multiple award winning plumbing company in ... 35 years. Maintaining core values of exceptional customer service, quality work at reasonable rates, ... leading name in San Diego plumbing, and other services including heating & air conditioning ...
Breaking Medicine News(10 mins):